Rein Therapeutics (NASDAQ: RNTX) details planned Phase 2 LTI-03 trial in UK

Rhea-AI Filing Summary

Rein Therapeutics, Inc. reported that it issued a press release about the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. The company used this report to formally note the communication to the market and attached the press release as an exhibit for investors to review.

The filing does not provide clinical, financial, or operational details about the Phase 2 trial itself, but directs readers to the full press release, dated August 19, 2025, for more information on the LTI-03 development plans.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

NASDAQ false 0001420565 0001420565 2025-08-19 2025-08-19

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 19, 2025

REIN THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-38130		13-4196017
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification Number)

12407 N. Mopac Expy., Suite 250, #390

Austin, Texas 78758

(Address of principal executive offices)

(737) 802-1989

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions.

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock: Par value $.001		RNTX		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On August 19, 2025, Rein Therapeutics, Inc. issued a press release concerning the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K. A copy of the press release is attached as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibits are filed with this report:

Exhibit 99.1		The Company’s press release dated August 19, 2025
Exhibit 104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				REIN THERAPEUTICS, INC.
Dated: August 19, 2025						/s/ Brian Windsor
						Brian Windsor, Ph.D.,
						President and Chief Executive Officer

FAQ

What did Rein Therapeutics (RNTX) disclose in this 8-K?

Rein Therapeutics disclosed that it issued a press release about the planned Phase 2 clinical trial of its LTI-03 product candidate in the U.K., and filed that release as an exhibit.

What is the subject of Rein Therapeutics' press release mentioned in the 8-K?

The press release concerns the planned Phase 2 clinical trial of Rein Therapeutics' LTI-03 product candidate in the U.K.

Which exhibit did Rein Therapeutics (RNTX) file with this 8-K?

Rein Therapeutics filed Exhibit 99.1, which is the company’s press release dated August 19, 2025, along with Exhibit 104, the cover page interactive data file.

Does this 8-K from Rein Therapeutics include financial statements?

No, this report only lists exhibits and notes a press release about a planned Phase 2 trial; it does not include financial statements.

Where can investors find details about the LTI-03 Phase 2 trial for Rein Therapeutics?

Details are provided in Rein Therapeutics’ press release dated August 19, 2025, which is attached to the report as Exhibit 99.1.